Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2025-10-14 Regulatory Filings
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
Regulatory Filings Classification · 100% confidence The document is a press release from Oculis Holding AG announcing that the company will be presenting its late-stage pipeline at upcoming industry events (Eyecelerator and AAO 2025). It provides details on the presentations, speakers, and the company's clinical programs. This type of corporate communication, which serves to inform the market about upcoming investor-facing activities and pipeline progress, is classified as an Investor Presentation (IP) or related corporate announcement. Given the focus on highlighting pipeline assets for investors at conferences, 'IP' is the most accurate category.
2025-10-14 English
Regulatory Filings 2025
Regulatory Filings
2025-10-09 English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 100% confidence The document is a short announcement (620 characters) regarding a notification of transactions by persons discharging managerial responsibilities (PDMRs). While it relates to director dealings, the document itself is a brief notification/announcement of the filing rather than the detailed transaction report itself. Given the short length and the nature of the announcement, it fits the criteria for a Director's Dealing (DIRS) notification.
2025-10-08 English
6-K
Regulatory Filings
2025-10-06 English
Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugabólgu, sem gæti orðið fyrsta taugaverndandi meðferð sinnar tegundar
Regulatory Filings Classification · 100% confidence The document is a press release from Oculis Holding AG announcing the initiation of a clinical trial program (PIONEER) for their drug candidate Privosegtor, following a meeting with the FDA. It includes details on the trial design, expected timelines, and financial runway, and concludes with a notice for an upcoming investor conference call. This is a standard corporate announcement regarding business operations and clinical development, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like Earnings Release (ER) or Annual Report (10-K).
2025-10-06 Icelandic
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
Regulatory Filings Classification · 100% confidence The document is a press release issued by Oculis Holding AG announcing the advancement of their drug candidate 'Privosegtor' into registrational trials following FDA feedback. It includes details on clinical trial programs, management commentary, and preliminary unaudited financial information (cash position). It is not a full financial report (10-K/IR), nor is it a transcript or a governance document. It functions as a corporate announcement regarding business operations and clinical development milestones, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-10-06 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.